Abstract
Despite improvements in the antifungal armamentarium and diagnostic modalities, invasive aspergillosis (IA) remains an important cause of morbidity and mortality in immunocompromised patients. There is an emergence of non-traditional groups at risk for IA, including intensive care unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and patients on immunomodulating drugs (TNF-α inhibitors). Identification of clinical risk factors for IA may help in determining which patients require risk modification and other prevention measures.
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications
-
Aspergillosis / etiology*
-
Aspergillosis / immunology
-
Aspergillosis / prevention & control*
-
Aspergillus / pathogenicity
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Immunocompromised Host*
-
Immunosuppressive Agents / adverse effects
-
Intensive Care Units
-
Organ Transplantation / adverse effects
-
Postoperative Complications / immunology
-
Postoperative Complications / microbiology
-
Postoperative Complications / prevention & control
-
Pulmonary Disease, Chronic Obstructive / complications
-
Risk Factors
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha